RxDoctor Payments Data

Richard Marchell, MD

Dermatology · Charleston, SCNPI 1487682779

Payments from drug & device makers

$1,451in general payments, 2019–2025

Across 18 payments — averaging $80.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$379
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$265
  • Johnson & Johnson$162
  • Sun Pharmaceutical Industries Inc.$155
  • Galderma Laboratories, L.p.$124
  • Comsort, Inc$100
  • plus $267 from 5 others

What the payments were for

  • Consulting fees$1007%
  • Food & beverage$1,18982%
  • Education$16211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,451 in reported general payments places this provider in the 30th percentile of 203 dermatology providers in South Carolina.

See all dermatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$253,619
Medicare patients
1,447
Services billed
3,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa45$872,248
Humira(Cf) PenAdalimumab41$421,328
OtezlaApremilast72$359,237
RinvoqUpadacitinib45$328,315
Dupixent PenDupilumab57$265,567
Dupixent SyringeDupilumab38$198,900
Humira PenAdalimumab12$163,481
ErivedgeVismodegib13$131,650
XolairOmalizumab27$70,815
Acitretin29$7,917
Clobetasol Propionate165$7,867
RasuvoMethotrexate/Pf12$6,771
Fluorouracil66$4,715
Doxycycline Hyclate92$3,623
Triamcinolone Acetonide168$2,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$379$328,31545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 203 dermatology providers in South Carolina.

Other dermatology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →